Physician profile
Nicholas Cassis, JR.
NPI 1063523512
$1,713.56
in general payments reported to CMS, 2019-2025
9 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $37.40 · 2021: $234 · 2022: $503 · 2023: $394 · 2024: $179 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,027.60 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $307.06 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $200.91 | 2022-2023 | Mounjaro, Jardiance |
| Dexcom, INC. | $92.51 | 2021-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $30.14 | 2023-2025 | Synthroid |
| Astrazeneca Pharmaceuticals Lp | $16.27 | 2021 | |
| Amgen INC. | $15.05 | 2021 | |
| Medtronic, INC. | $12.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Cassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.